Sign in
4

Changes in Ownership

Stoke Therapeutics, Inc. Filed Acc 0001522780-25-000009

Director sold 15,001 shares at an average $31.13 ($466,959)

  • Director acquired 26,250 shares (option exercise)
  • Traded under a Rule 10b5-1 plan

From the SEC's structured data for this filing

Trades in this filing

Kaye Edward M. MD · Director

Table I: Non-derivative

6 lines
Date Transaction Shares Price Value Owned after D/I
2025-12-03 Exercise or conversion : show line 1 in the form 10b5-1 +26,250 77,555 D
2025-12-04 Sale : show line 2 in the form 10b5-1 −5,222 $30.76 $160,647 72,333 D
2025-12-04 Sale : show line 3 in the form 10b5-1 −1,231 $31.32 $38,550 71,102 D
2025-12-05 Sale : show line 4 in the form 10b5-1 −6,367 $31.33 $199,481 64,735 D
2025-12-05 Sale : show line 5 in the form 10b5-1 −1,681 $31.15 $52,358 63,054 D
2025-12-05 Sale : show line 6 in the form 10b5-1 −500 $31.85 $15,923 62,554 D
Open-market sales · 15,001 sh · avg $31.13 · $466,959

Table II: Derivative

1 line
Date Transaction Shares Owned after D/I
2025-12-03 Exercise or conversion : show line 7 in the form 10b5-1 Performance Stock Units −26,250 0 D
Loading xslF345X05/form4-12062025_011216.xml…